Trial · NCT02959411
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in body weight | From randomization to 96 hours after randomization | |
| Secondary | Total 96 hour urine output | From randomization to 96 hours post randomization | Measured in ml urine |
| Secondary | Subjective change in shortness of breath | 48 hours after randomization and 96 hours post randomization | As assessed by a 5 point Likert scale |
| Secondary | Change in renal function | From randomization to 7 days post randomization | Measured by estimated glomerular filtration rate |
| Secondary | Proportion of patients developing worsening renal function (WRF) | From randomization to 7 days post randomization | Categorical measure- need for renal replacement therapy or ultrafiltration or increase in serum creatinine by \> 26 umol/L |
| Secondary | Change in serum sodium | From randomization to 7 days post randomization | Measured in mmol/L |
| Secondary | Length of hospitalization | From hospital admission to 30 days post randomization | Number of days in hospital |
| Secondary | Need for intensive care unit admission | From hospital admission to 30 days post randomization | Categorical measure (yes/no) |
| Secondary | Need for positive inotropic agent use | From randomization to 7 days post randomization | Categorical measure (yes/no) |
| Secondary | Composite of Worsening Renal Function or need for inotropic agent | From randomization to 7 days post randomization | Worsening Renal Function defined as increase from serum creatinine at randomization of more than 30 umol/L at any time from randomization to 7 days. This is a categorical outcome (yes/no) |
| Secondary | 30 day cardiovascular death and/or hospitalization | From Randomization to 30 days post randomization | Categorical outcome (yes/no) |
| Secondary | Clinical markers of congestion | From randomization to 96 hours after randomization | Described as total number of the presence of Jugular venous pressure (JVP) level, edema, rales, orthopnea, 3rd heart sound |
| Secondary | Change in N-terminal brain natriuretic peptide (NT-pro BNP) | From randomization to 96 hours post randomization compared to baseline | Measurement calculated in absolute value of NT-pro-BNP |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02959411/registered